Welcome to Sysmex Inostics
Empowering discoveries in oncology
We provide ultra-sensitive liquid biopsy solutions for exceptional ctDNA detection. We partner with BioPharma companies to aid cancer drug and diagnostic development to monitor therapy response, identify targetable resistance, and detect minimal residual disease (MRD).
Approach
Our Products & Solutions
Sensitive and specific liquid biopsy
News & Events
The latest
Sysmex Inostics Introduces CLIA-Validated Highly Sensitive HNSCC-SEQ Testing Services for Head and Neck Cancer at the 2022 Molecular Medicine Tri-Conference
Presenting Poster of Clinical Trial Findings at 2022 Multidisciplinary Head and Neck Cancers Symposium Baltimore,…
University of Chicago Clinical Trial Utilizes Sysmex Inostics Highly Effective HPV-SEQ Test to Measure HPV-DNA from Blood of Neck and Throat Cancer Patients
Baltimore, MD, January 26, 2022 – Sysmex Inostics, a global leader in the liquid biopsy…
New Ultra-Sensitive Leukemia Blood Test Delivered by Sysmex Inostics
Sysmex Inostics has developed a new CLIA-validated liquid biopsy test for the detection of Minimal…